Study of Platelet Activity in Adults With Ventricular Assist Devices VAD Using Advanced Blood Tests

What this Trial Is About

Researchers are investigating how the blood clotting and platelet function change in patients with end-stage heart failure who receive mechanical circulatory support devices such as percutaneous microaxial pumps Impella, extracorporeal membrane oxygenators ECMO, or Ventricular Assist Devices VAD. The study aims to understand how these devices interact with the bloods clotting system and antithrombotic drugs to identify causes of clotting or bleeding complications and potential treatment targets. The study uses two innovative tests to evaluate platelet function the Platelet Activity State PAS assay and the Thrombin Generation Test TGT. These tests are performed at several points before device implantation to establish baseline values, early after implantation during hospital stay, throughout long-term follow-up, and when complications or therapy changes occur. Alongside these tests, standard blood parameters related to coagulation and hemolysis are measured, and device function data such as pump speed and power use are recorded. Participants are monitored for up to 24 months with evaluations at 1, 3, 6, 12, 18, and 24 months after device implantation, as well as when any adverse events happen. Researchers track changes in platelet activity, coagulation markers, device parameters, and antithrombotic therapies. The study focuses on understanding how these factors relate to post-implant complications to improve patient care and device management.

Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD)